We conclude that hepatocyte Arg2 is a critical effector of the hepatic glucose fasting response and define a therapeutic target to mitigate the complications of obesity and non-alcoholic fatty liver disease. This evidence concerns the gene ARG2 and metabolic dysfunction-associated steatotic liver disease.